A recent study indicates that propranolol, a beta-blocker commonly prescribed for migraine prevention, may significantly reduce the risk of ischemic stroke in women suffering from migraines. This research was presented at the American Stroke Association's International Stroke Conference 2025, to be held from February 5 to 7 in Los Angeles.

The study, led by Dr. Mulubrhan Mogos from Vanderbilt University School of Nursing, analyzed data from two extensive electronic health record databases: the Synthetic Derivative at Vanderbilt University Medical Center and the All of Us Research Program. The researchers identified migraine patients and compared those who experienced a stroke after their first migraine diagnosis to those who did not. Their findings revealed that female migraine patients using propranolol had a significantly lower risk of stroke, particularly ischemic stroke, compared to those not using the medication. This protective effect was not observed in male patients.

Dr. Mogos emphasized the importance of these findings, stating, "Many women suffer from migraines, and it's important to note that propranolol may be beneficial for these women, particularly those who experience migraine without aura."

While propranolol is already established as an effective preventive treatment for migraines, this study suggests an additional benefit in reducing stroke risk among women. However, further research is necessary to understand the underlying mechanisms and to explore why this protective effect is not seen in men.

These findings could influence future guidelines for migraine management, particularly in women at elevated risk for ischemic stroke.